Diagnostic Or Test Agent Produces In Vivo Fluorescence Patents (Class 424/9.6)
-
Publication number: 20150125396Abstract: Described are methods for the detection, in the eye of an individual, of protein aggregates or other misfolded proteins associated with disease using peptide or peptide mimic probes that preferentially associate with the protein aggregates or misfolded proteins, which can be accomplished non-invasively.Type: ApplicationFiled: June 5, 2014Publication date: May 7, 2015Applicant: Adlyfe, Inc.Inventors: Giora Feuerstein, Richard Cliff
-
Publication number: 20150118156Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.Type: ApplicationFiled: December 23, 2014Publication date: April 30, 2015Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
-
Publication number: 20150118162Abstract: The present disclosure relates to a two-photon fluorescent dye for imaging total sulfide in vivo and a method for quantitatively estimating total sulfide concentration in vivo using the same. The two-photon fluorescent dye, which includes a compound of [Chemical Formula 1], can detect hydrosulfide on and image total sulfide and allows quantitative estimation of total sulfide concentration in vivo.Type: ApplicationFiled: August 14, 2014Publication date: April 30, 2015Inventor: Bong-Rae Cho
-
Publication number: 20150118154Abstract: The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer.Type: ApplicationFiled: January 8, 2015Publication date: April 30, 2015Inventors: Marco Alifano, Patricia Forgez
-
Publication number: 20150118163Abstract: The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.Type: ApplicationFiled: October 30, 2014Publication date: April 30, 2015Inventors: Haresh Bhagat, Gerald D. Cagle, Francis X. Smith, Paul D. Hartung
-
Patent number: 9017646Abstract: A process of evaluating blood-brain barrier permeability of a stroke rat by using fluorescent substance is disclosed. This process uses an Evans blue dye having spontaneous fluorescence properties, in combination with the use of a new non-invasive in vivo imaging system (IVIS), to obtain fluorescent signals so as to assess the change in the blood-brain barrier permeability of rodents after a cerebral artery stroke model surgery. In operation, an Evans blue dye is injected into a stroke rat of middle cerebral artery occlusion model. A non-invasive in vivo imaging system is used to detect the fluorescence distribution of the whole brain, and obtain images combined by the fluorescence images and optical images for the whole brain tissue. Thereby, the change in the blood-brain barrier permeability of the stroke rat can be completely realized.Type: GrantFiled: July 10, 2012Date of Patent: April 28, 2015Assignee: Institute of Nuclear Energy Research, Atomic Energy CouncilInventors: Jun-Ming Shih, Yuan-Ruei Huang, Yu-Lung Wu, Shih-Ying Lee, Kang-Wei Chang, Chia-Chien Chen
-
Publication number: 20150110719Abstract: Described are catheters associated with a hydrogel for release of a molecule of interest. The molecule of interest may be an antibody. Further described are sensors useful for detecting the presence or amount of an analyte, and associated methods. A sensor for use in detecting the presence or amount of an analyte may comprise a catheter having one or more apertures. The sensor may also include means for detecting binding of the analyte to an antibody.Type: ApplicationFiled: May 8, 2013Publication date: April 23, 2015Inventors: Zhao Jie, Li Min She
-
Publication number: 20150110720Abstract: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.Type: ApplicationFiled: September 25, 2014Publication date: April 23, 2015Applicant: STC.UNMInventors: ANATOLIY MARKIV, RAVI VENKATA DURVASULA, ANGRAY SINGH KANG
-
Publication number: 20150104394Abstract: A method for observing the morphology of a biological tissue is disclosed. The method involves using a fluorescent dye on the biological tissue, where the fluorescent dye is selected from patent blue V, isosulfan blue, toluidine blue, hypericin, indocyanine green, MVAC, or doxorubicin, and using a microscopic linear or non-linear imaging system to form an image of the biological tissue, where the fluorescence of the dye reveals the morphology of the tissue at cellular scale.Type: ApplicationFiled: May 17, 2013Publication date: April 16, 2015Applicant: IGR-Institut Gustave RoussyInventors: Muriel Abbaci, Odile Casiraghi, Corinne Laplace-Builhe
-
Publication number: 20150104395Abstract: Methods and systems for distinguishing an astrocytic human brain rumor from a non-astrocytic human brain tumor (FIG. 4). In one embodiment a method includes the steps of staining tumor tissue from a subject suspected of having a brain tumor with SR101 and visualizing the tissue stained with SR101 with a fluorescence imaging device to confirm an astrocytic or non-astrocytic tumor type. Advantageously, rumor tissue from a subject is stained ex vivo, and the staining and visualizing steps are performed intraoperatively so as to guide the surgeon and thereby minimize or eliminate the need for a subsequent surgery.Type: ApplicationFiled: June 3, 2013Publication date: April 16, 2015Applicant: Dignity HealthInventors: Joseph Georges, Nikolay Martirosyan, Peter Nakaji
-
Publication number: 20150105619Abstract: Endoscopic devices and methods for imaging and treating organs and tissues are described. The endoscopic devices described herein include flexible endoscopes, rigid endoscopes, and capsule endoscopes. The endoscopic device may comprise one or more cameras and one or more light sources. In some embodiments, the endoscopic device comprises at least one white light camera, at least one blue light camera, at least one white light source, and at least one blue light source. In some embodiments, fluorescent targeting constructs can be injected into the subject and bound to and/or taken up by a tumor or diseased tissue. Diseased tissue can be identified by viewing the fluorescence emanating from the fluorescent targeting constructs by illuminating an in vivo body part of the subject with light having at least one excitation wavelength in the range from 400 nm to about 510 nm.Type: ApplicationFiled: April 16, 2013Publication date: April 16, 2015Applicant: Oncofluor, Inc.Inventor: George A. Luiken
-
Publication number: 20150104387Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.Type: ApplicationFiled: April 2, 2014Publication date: April 16, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
-
Publication number: 20150104396Abstract: A method of detecting an accessory cancer lesion, comprising an administration step wherein indocyanine green is administered to a living body, an irradiation step wherein a target organ suspected of having cancer is surgically exposed and irradiated with excitation light of indocyanine green, an imaging step wherein a near-infrared fluorescence intensity distribution image from the excited indocyanine green in the target organ is obtained, and an identification step wherein an area having the near-infrared fluorescence in the intensity distribution image, excluding the area detected in preoperative examination or intraoperative macroscopic observation, is identified as an accessory cancer lesion.Type: ApplicationFiled: December 19, 2014Publication date: April 16, 2015Inventors: Osamu Ishikawa, Terumasa Yamada, Kunihito GOTOH, Mitsuharu Miwa, Takahiro Shikayama
-
Patent number: 9005582Abstract: A medical delivery system that enables the delivery of therapeutic agents to malignant tissue utilizing delivery agents and heating of the delivery agents thereby causing the release of the therapeutic agents within the tumor is disclosed. The therapeutic agents may be chemotherapy agents, radiation therapy agents, and other appropriate materials. The magnetic nanoparticles encapsulated by the therapeutic agents in a biocompatible coating may be delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites. An alternating magnetic field device with a prescribed frequency range may be used to induce heating of the magnetic nanoparticles in the patient thereby melting the coating and releasing the therapeutic agents within the tumor.Type: GrantFiled: December 20, 2012Date of Patent: April 14, 2015Assignees: University of North Carolina at Greensboro, United Arab Emirates UniversityInventor: Yousef Haik
-
Publication number: 20150098905Abstract: The present invention relates to targeting agents and methods: of using the targeting agents to detect a fungal cell in a subject.Type: ApplicationFiled: May 8, 2013Publication date: April 9, 2015Applicant: Rutgers, The State University of New JerseyInventors: David S. Perlin, Guillermo Garcia-Effron, Arkady Mustaev
-
Patent number: 8999296Abstract: Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.Type: GrantFiled: April 21, 2009Date of Patent: April 7, 2015Assignees: Kochi University, SBI Pharmaceuticals Co., Ltd.Inventors: Keiji Inoue, Masahiro Ishizuka, Tohru Tanaka
-
Patent number: 8999290Abstract: Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).Type: GrantFiled: February 8, 2013Date of Patent: April 7, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeff Roberts, Douglas R. Lowy, John T. Schiller
-
Publication number: 20150093332Abstract: A tumor-targeting multi-mode imaging and analyzing method for living body based on gold nanoclusters can include incubating the relevant cells with chloroauric acid and the salt solution thereof with certain concentration under physiological conditions, thereby generating gold nanoclusters. After, real-time non-invasive fluorescence imaging, Raman imaging and/or ultrasonic imaging can be used to image the tumor tissue.Type: ApplicationFiled: December 11, 2014Publication date: April 2, 2015Inventors: Xuemei Wang, Jianling Wang, Qiwei Li, Hui Jiang
-
Publication number: 20150093334Abstract: A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an organism, to a specific tissue, to specific cells, or to an environmental medium, by sequestering the one or more than one substance within a vault-like particle. A method of delivering one or more than one substance or a sensor to an organism, to a specific tissue, to specific cells, or to an environmental medium. According to another embodiment of the present invention, there is provided a method of making vault-like particles, and making vault-like particles comprising one or more than one substance, or one or more than one sensor.Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Leonard H. Rome, Valerie A. Kickhoefer, Sujna Raval-Fernandes, Phoebe Stewart
-
Publication number: 20150093333Abstract: Embodiments herein report compositions, systems, methods, and uses for diagnosing and/or treating a condition in a subject. In certain embodiments, one or more peptides can be used as biomarker detectors for predicting onset or progression of disease. Some embodiments of the present invention report peptides capable of associating with MVs for predicting onset or progression of cancer in a subject. Other embodiments include methods of generating and or modifying peptides of use herein. Yet other embodiments herein report biomarker detectors capable of detecting agents associated with cancer progression, for example, metastasis.Type: ApplicationFiled: August 30, 2012Publication date: April 2, 2015Inventors: Hang Yin, Jonel P. Saludes, Leslie Morton
-
Publication number: 20150093329Abstract: The invention provides methods and products, such as kits, useful for determining the apoptotic state of cells in an organism, comprising detecting the presence or abundance of at least one caspase affinity labeling agent in the cells of an animal into which at least one caspase affinity labeling agent has been introduced, wherein the presence or abundance of the caspase affinity labeling agent correlates with the apoptotic state of the cells.Type: ApplicationFiled: September 12, 2014Publication date: April 2, 2015Applicant: SEED RESEARCH AND DEVELOPMENT, LLCInventors: Gary Johnson, Brian W. Lee
-
Patent number: 8992886Abstract: Compositions, methods of using and methods of making a cyclic peptide analog imaging agent that includes at least portions of a peptide or protein that binds specifically to the GLP-1 receptor (GLP-1R) and the cyclic analog has one or more conformational restrictions including, but not limited to, lactam bridges, disulfide bridges, hydrocarbon bridges, and their combinations, salts and derivatives thereof wherein the cyclic analog is more stable than a non-cyclic analog when incubated in the presence of enzymes that degrade GLP-1 and have an increased serum half-live, wherein the cyclic analog comprises at least a portion of a GLP-1 peptide or at least a portion of an Exendin peptide salts, derivatives or combinations thereof.Type: GrantFiled: April 6, 2010Date of Patent: March 31, 2015Assignee: Board of Regents, the University of Texas SystemInventors: Jung-Mo Ahn, Xiankai Sun
-
Publication number: 20150086479Abstract: The invention provides a process for forming a layered nanoparticle, comprising providing a suspension comprising a core particle in a first liquid, adding a second liquid to the suspension, and adding a reagent, or a precursor for the reagent, to the suspension. The second liquid is immiscible with the first liquid. If the reagent is added to the suspension, the reagent reacts to form a layer on the core particle to form the layered nanoparticle. If a precursor for the reagent is added to the suspension, the precursor is converted to the reagent, and the reagent reacts to form a layer on the core particle to form the layered nanoparticle.Type: ApplicationFiled: September 4, 2014Publication date: March 26, 2015Inventors: Christophe Jean Alexandre BARBE, Linggen KONG
-
Patent number: 8986652Abstract: The present invention provides a method of preparing [123I]Iodooctyl fenbufen amide with a radiochemical yield of 15%, a specific activity of 37 GBq/?mol and radiochemical purity of 95%. The present invention further provides a method of applying [123I]Iodooctyl fenbufen amide as tracer of single photon emission computer tomography (SPECT) to estimate the distribution of cyclooxygenase. By the binding characteristics of the iodine isotope-labeled compounds and the positive correlation of inflammation to tumor lesion, the present invention can estimate the tumor development and metastasis.Type: GrantFiled: February 1, 2013Date of Patent: March 24, 2015Assignee: National Tsing Hua UniversityInventors: Chung-Shan Yu, Ho-Lien Huang, Chun-Nan Yeh, Wei-Yuan Lee, Kang-Wei Chang, Ying-Cheng Huang, Kun-Ju Lin, Ching-Shiuann Yang, Shu-Fan Tien, Wen-Chin Su, Jenn-Tzong Chen, Wuu-Jyh Lin, Shiou-Shiow Farn
-
Patent number: 8986656Abstract: An object of the present invention is to provide a method for accurately evaluating the specific incorporation of D-glucose into cells. The present invention as a means for achieving the object is characterized by comprising contacting a D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells and an L-glucose derivative that has a fluorescent chromophore in the molecule with different cells in the same cell strain to be evaluated, respectively, comparing the fluorescence emitted by the D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells with the fluorescence emitted by the L-glucose derivative that has a fluorescent chromophore in the molecule, and evaluating the specific incorporation of D-glucose into cells relative to L-glucose by taking the difference between the two kinds of fluorescence intensities.Type: GrantFiled: August 7, 2009Date of Patent: March 24, 2015Assignees: Hirosaki University, National University Corporation Tokyo Unversity of Agriculture and TechnologyInventors: Katsuya Yamada, Hideaki Matsuoka, Tadashi Teshima, Toshihiro Yamamoto
-
Patent number: 8986657Abstract: The present invention provides methods of detecting soluble amyloid ? using curcumin-derived near infrared (NIR) imaging probes. Upon interacting with soluble amyloid ?, these probes undergo a range of changes, qualifying them as “smart” probes. In addition, the invention provides methods of detecting soluble amyloid ? by positron emission tomography (PET), magnetic resonance imaging (MRI) and multimodal imaging based on the curcumin-derived NIR imaging probes and derivatives thereof.Type: GrantFiled: July 29, 2010Date of Patent: March 24, 2015Assignee: The General Hospital CorporationInventors: Chongzhao Ran, Anna Moore
-
Publication number: 20150080721Abstract: The present disclosure provides methods for detecting a tumor microenvironment, a peritumoral tissue, or a portion thereof using a chlorotoxin conjugate. Also provided are chlorotoxin peptides and variants thereof conjugated to a detectable label for use in detecting a tumor microenvironment, a peritumoral tissue, or a portion thereof.Type: ApplicationFiled: September 17, 2014Publication date: March 19, 2015Inventors: Julia E. Novak, Stacey J. Hansen, William S. Dernell, Katie C. Kennedy, Valorie R. Wiss
-
Publication number: 20150079004Abstract: In a general embodiment, a method for increasing efficacy of a swallow response is provided. The method includes providing a thickened composition having a xanthan gum thickening component, and orally administering the composition to an individual having, or at risk of having, a swallowing impairment. In an embodiment, the efficacy of the swallow response is increased by reducing an amount of pharyngeal residue in the individual's piriform sinuses, valleculae, and/or pharyngeal wall during or after the individual swallows the composition.Type: ApplicationFiled: April 19, 2013Publication date: March 19, 2015Applicant: NESTEC S.A.Inventors: Michael Jedwab, Adam Burbidge, Kala Marie Kaspar, Julie Ann Swanson
-
Publication number: 20150071860Abstract: A micelle comprising a diblock polymer with a cyclic polyethylene glycol block and a hydrophobic block is provided. The micelle may be used in conjunction with one or a combination of therapeutic agents, targeting agents, and imaging agents. The micelle may be incorporated in a pharmaceutical composition.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventors: Coleen Pugh, Gladys R. Montenegro-Galindo
-
Publication number: 20150071859Abstract: The present disclosure encompasses embodiments of nucleic acid minicircle vectors most advantageous for the detection of tumor cells. In particular, the minicircles of the disclosure incorporate a tumor-specific promoter operably linked to a nucleotide sequence desired to be selectively expressed in a tumor cell or a tissue comprising a population of tumor cells. In embodiments of the disclosure, the minicircle vectors comprise a tumor-specific promoter operably linked to a nucleotide sequence encoding a polypeptide useful as a reporter. Accordingly, when expressed by a recipient tumor cell, the reporter may be detectable, thereby providing information such as a visual image of the tumor cell and/or its location in a tissue of the subject human or non-human animal.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventors: Sanjiv S. Gambhir, John A. Ronald
-
Publication number: 20150071863Abstract: The invention relates to compositions of DOTA derivative compounds, lanthanoid-DOTA derivative molecular complex, and lanthanoid-complex encapsulated solid lipid particles or capsules, and methods of making and using the compositions. The solid lipid particles or capsules contain micelle cores stabilized by a hyperbranched polymer shell based from a crosslinked DOTA derivative compound or crosslinked lanthanoid-DOTA derivative complex. These solid lipid particles or capsules can be used in various applications, such as contrast agents or drug delivery vehicles.Type: ApplicationFiled: September 22, 2014Publication date: March 12, 2015Inventor: Marc Anton WALTERS
-
Publication number: 20150064107Abstract: The invention relates to imaging agents, and in particular to multi-modal nanoparticle (NPIA) imaging agents offering magnetic, radionuclide and fluorescent imaging capabilities to exploit the complementary advantages of magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging (OI). The invention extends to these new types of agents per se, and to uses of such agents in various biomedical applications, such as in therapy and in diagnosis.Type: ApplicationFiled: August 28, 2014Publication date: March 5, 2015Applicant: King's College LondonInventors: Xianjin Cui, Philip Blower, Mark A. Green
-
Patent number: 8968704Abstract: Provided is a fluorescent labeling material, including zinc oxide nanoparticles each surface-modified with an organic compound having an amino group placed at an outer end thereof. Also provided is a fluorescent labeling agent to be used in vivo or in vitro, including the fluorescent labeling material, in which: EDC or the like is bound thereto through the amino group; and a substance capable of selectively binding to a target to be fluorescently labeled, such as an antibody, is linked thereto.Type: GrantFiled: April 29, 2011Date of Patent: March 3, 2015Assignee: National University Corporation Shimane UniversityInventors: Moriyuki Sato, Morihiko Nakamura
-
Patent number: 8968705Abstract: The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.Type: GrantFiled: February 17, 2010Date of Patent: March 3, 2015Assignee: Colorado School of MinesInventors: Stephen G. Boyes, Misty D. Rowe
-
Patent number: 8968789Abstract: The present invention is directed to sulfonic esters of metal oxides including those of formulas I and II:Type: GrantFiled: February 12, 2014Date of Patent: March 3, 2015Assignees: California Institute of Technology, Children's Hospital of Los AngelesInventors: Carl M. Blumenfeld, Harry B. Gray, Robert H. Grubbs, Karn Sorasaenee
-
Patent number: 8968700Abstract: Methods and materials for the imaging of cells containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in a fluorescent signal due to removal of a quenching group which, when present on the probe causes altered or no fluorescence. The probes employ an acyloxymethyl ketone reactive group, one or more amino acids for determining specificity, a fluorophore and a quencher. The probes are cell permeable and may use, for example, a QSY7 (diarylyrhodamine) quencher and a BODIPY (bora-diaza-indecene) dye.Type: GrantFiled: August 10, 2006Date of Patent: March 3, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Matthew S. Bogyo, Galia Blum, Georges von Degenfeld
-
Publication number: 20150056142Abstract: Embodiments of the present disclosure provide for compositions including organic, water-soluble NIR-II fluorescent agent that emit radiation at about 1.0 to 1.7 ?m, methods of making the composition, methods of imaging a disease and related biological events, methods of imaging, monitoring and/or assessing a disease and related biological events, and the like.Type: ApplicationFiled: August 20, 2014Publication date: February 26, 2015Inventors: Zhimin Tao, Guosong Hong, Yingping Zou, Chihiro Fukunaga, Hongjie Dai, Shuo Diao, Alex Antaris
-
Publication number: 20150056137Abstract: Provided is an activatable probe that undergoes intramolecular cyclization and subsequent aggregation in apoptotic tumor cells upon peptidase-initiated, and most advantageously caspase-3, activation. These caspase-sensitive nano-aggregation probes (C-SNAFs) are generally biocompatible, possess NIR spectral properties or may serve as PET or MRI imaging agents, and have a mechanism of target-mediated nanostructure self-assembly amenable to in vivo use. The probes encompass biocompatible condensation chemistry products that comprise D-cysteine and 2-cyano-6-hydroxyquinoline (CHQ) moieties linked to an amino-luciferin scaffold, and which can be activated by a two-step reaction requiring caspase-3/7-mediated cleavage of an aspartate-glutamate-valine-aspartate (L-DEVD) capping peptide and the free intracellular thiol-mediated reduction of the disulfide bond.Type: ApplicationFiled: August 20, 2014Publication date: February 26, 2015Inventors: Jianghong Rao, Deju Ye, Adam Shuhendler, Frederick Te-Ning Chin, Jongho Jeon, Bin Shen
-
Publication number: 20150056146Abstract: There is provided a composition used for contrast imaging, the composition containing an aqueous solution containing a J-aggregate of indocyanine green and at least one storage stabilizer selected from the group consisting of alkali metal ions, alkaline earth metal ions, and an ammonium ion.Type: ApplicationFiled: August 15, 2014Publication date: February 26, 2015Inventor: Kouichi Kato
-
Publication number: 20150056133Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.Type: ApplicationFiled: August 20, 2014Publication date: February 26, 2015Inventors: Alisa K. WATERMAN, Nick Mark Devoogdt, Tony Lahoutte, Matthias SCHNEIDER, Sanjaya SINGH, Cedric Jozef Néotère VERVERKEN
-
Publication number: 20150056143Abstract: A hydrogel-lightguide based sensory system susceptible to a stimulus signal produced by ambient and stimulating sensory cells embedded in a hydrogel body of the system. Sensory cells generate an optical signal (in response to a user-defined triggering with excitation light or, alternatively, due to bioluminescence) the properties of which, determined based on detection of such signal with an optical detector device, provide characterization of the stimulus and information required for user-defined activation of emitter cells encapsulated in the hydrogel. When activated, emitter cells generate matter and/or light directed to interact with the ambient.Type: ApplicationFiled: October 17, 2014Publication date: February 26, 2015Inventors: Seok-Hyun Yun, Myunghwan Choi
-
Patent number: 8961937Abstract: The present invention relates to a composition for detecting beta amyloid aggregates and a composition for diagnosing beta amyloid aggregation disease, comprising a 2-styrilpyridizine-3(2H)-one derivative or its pharmaceutically acceptable salt, to a diagnostic kit for diagnosing beta amyloid aggregation disease comprising said composition and to a method for detecting beta amyloid aggregates using said compositions to provide information for beta amyloid aggregation disease diagnosis.Type: GrantFiled: March 13, 2013Date of Patent: February 24, 2015Assignee: Korea Atomic Energy Research InstituteInventors: Yong Dae Park, Jeong Hoon Park, Yong Jin Yoon, Seung Tae Yang, Min Goo Hur
-
Patent number: 8961928Abstract: A ligand and a metal complex having the ligand are provided. The ligand and a paramagnetic metal ion form a metal complex with high stability, high relaxivity and high biocompatibility. The metal complex of the present invention is applicable to the preparation of MRI contrast agents for detecting atherosclerosis. The MRI contrast agent includes a peptide sequence specific to a matrix metalloprotease, and can be recognized by a pathological thrombocyte to target a specific site, so as to enhance the imaging contrast.Type: GrantFiled: May 9, 2012Date of Patent: February 24, 2015Assignee: National Chiao Tung UniversityInventors: Yun-Ming Wang, Gin-Chung Liu, Chiao-Yun Chen, Teng-Wen Li
-
Publication number: 20150050212Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.Type: ApplicationFiled: February 22, 2013Publication date: February 19, 2015Inventors: Philip S. Low, Charity Wayua
-
Publication number: 20150050211Abstract: Provided herein are methods to generate and screen peptides that exhibit drug like stabilities in vitro and in vivo. By selecting for enzyme resistance, Applicants are able to derive peptides that are not only stable to a broad spectrum of proteases, but also stable to other drug processing enzymes such as cytochrome P450s. This approach provides a general method to the rapid development of highly stable peptides for therapeutic development and diagnosis. The peptides are further modified for oral bioavailability.Type: ApplicationFiled: August 31, 2012Publication date: February 19, 2015Applicant: University of Souththern CaliforniaInventors: Stephen V. Fiacco, Terry T. Takahashi, Richard W. Roberts
-
Patent number: 8957215Abstract: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: GrantFiled: April 23, 2012Date of Patent: February 17, 2015Assignee: Navidea Biopharmaceuticals, Inc.Inventors: Ylva Gravenfors, Catrin Jonasson, Jonas Malmstrom, Gunnar Nordvall, David Pyring, Can Slivo, Daniel Sohn, Peter Strom, David Wensbo
-
Patent number: 8956591Abstract: A method of detecting an accessory cancer lesion, comprising an administration step wherein indocyanine green is administered to a living body, an irradiation step wherein a target organ suspected of having cancer is surgically exposed and irradiated with excitation light of indocyanine green, an imaging step wherein a near-infrared fluorescence intensity distribution image from the excited indocyanine green in the target organ is obtained, and an identification step wherein an area having the near-infrared fluorescence in the intensity distribution image, excluding the area detected in preoperative examination or intraoperative macroscopic observation, is identified as an accessory cancer lesion.Type: GrantFiled: May 14, 2009Date of Patent: February 17, 2015Assignees: Osaka Prefectural Hospital Organization, Hamamatsu Photonics K.K.Inventors: Osamu Ishikawa, Terumasa Yamada, Kunihito Gotoh, Mitsuharu Miwa, Takahiro Shikayama
-
Publication number: 20150044143Abstract: The invention relates to a family of dyes which fluoresce in the UV-VIS, far red and near infrared wavelengths of the spectrum and possess asymmetric lipophilic alkyl chains. The dyes of the invention are soluble in commercially available membrane staining dyes, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well-retained therein. Methods of utilizing the dyes to detect stained cells both in vivo and in vitro are also disclosed.Type: ApplicationFiled: October 23, 2014Publication date: February 12, 2015Applicant: PHANOS TECHNOLOGIES, INC.Inventor: Brian D. Gray
-
Publication number: 20150044140Abstract: The peptides of formula (I) R1—(X)K—P—Y, where: R1 is the group attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and is selected from H, CH3C(?O)—, and maleimide; X is a biradical selected from —NH—(CH2)r—C(?O)—, —C(?O)—(CH2)r—C(?O)—, —S(CH2)r—, —S—(CH2)r—C(?O)—, —O—(CH2)r—, —S—CH2—CH(NH2)—C(?O)—, —O—(CH2)r—C(?O)—, —(CH2)r—C(?O)—, —NH—O—CH2—C(?O)—NH—(CH2)r—CH(NH2)—C(?O)—, —(CH2)r—C(?O)—NH—(CH2)r—CH(NH2)—C(?O)—, and —NH—(CH2)r—CH(NHC(?O)CH2NH2)—C(?O)—; r is 1-5; P is a biradical of an amino acid sequence comprising the sequence D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 1); Y is the group attached to the C-terminal of the last amino acid of the sequence P, and is selected from —NH2, —OH, —OR2 and —NHR2; R2 is a radical selected from (C1-C6)-alkyl and (CH2)2—NH—C(?O)—CH2—O—NH2; k is 0-2; m is 0-1; with the proviso that when the biradical X is —C(?O)(CH2)rC(?O)—, then R1 is H; when the N of the amino acid of the sequence PType: ApplicationFiled: February 27, 2013Publication date: February 12, 2015Inventors: Ernest Giralt Lledó, Meritxell Teixidó Turà, Roger Prades Cosano
-
Publication number: 20150044135Abstract: The invention described herein relates to the detection, diagnosis, and treatment of intestinal metaplasias that develop to esophageal, gastric, and pancreatic adenocarcinoma. The stem cells and differentiated cells of these intestinal metaplasias show high expression of CDH17 as well as other proteins. The invention also includes a clonal population of Barrett's esophagus stem cells as well as the stem cells of the surrounding normal epithelia and methods of using them for the detection, diagnosis, and treatment of Barrett's esophagus.Type: ApplicationFiled: September 24, 2014Publication date: February 12, 2015Inventors: Wa Xian, Frank McKeon, Matthew Vincent, Khek Yu Ho